Healthcare provider profile · identity verified

James E Gore, MD

Rheumatology · NASHVILLE, TN · NPI 1316975485

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Prednisone	Prednisone	1133	308
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	784	230
Methotrexate	Methotrexate Sodium	552	148
Gabapentin	Gabapentin	377	101
Tramadol Hcl	Tramadol Hcl	255	45
Rinvoq	Upadacitinib	254	30
Diclofenac Sodium	Diclofenac Sodium	228	100
Meloxicam	Meloxicam	202	60
Enbrel Sureclick	Etanercept	201	23
Xeljanz	Tofacitinib Citrate	189	20
Colchicine	Colchicine	175	55
Pregabalin	Pregabalin	160	32
Humira(Cf) Pen	Adalimumab	148	20
Sulfasalazine	Sulfasalazine	144	38
Mycophenolate Mofetil	Mycophenolate Mofetil	142	35
Methylprednisolone	Methylprednisolone	128	40
Folic Acid	Folic Acid	124	34
Famotidine	Famotidine	121	40
Sulfasalazine Dr	Sulfasalazine	118	35
Leflunomide	Leflunomide	117	32
Leucovorin Calcium	Leucovorin Calcium	117	33
Enbrel	Etanercept	113	12
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	113	33
Celecoxib	Celecoxib	112	40
Alendronate Sodium	Alendronate Sodium	104	32
Kineret	Anakinra	99	15
Azathioprine	Azathioprine	98	31
Orencia Clickject	Abatacept	98	16
Rasuvo	Methotrexate/Pf	97	suppressed
Allopurinol	Allopurinol	93	24
Benlysta	Belimumab	93	suppressed
Duloxetine Hcl	Duloxetine Hcl	89	24
Orencia	Abatacept	88	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	85	25
Simponi	Golimumab	84	12
Methotrexate Sodium	Methotrexate Sodium/Pf	79	18
Nabumetone	Nabumetone	73	25
Humira Pen	Adalimumab	70	suppressed
Otezla	Apremilast	70	suppressed
Actemra Actpen	Tocilizumab	66	suppressed
Cevimeline Hcl	Cevimeline Hcl	62	18
Cosentyx Sensoready (2 Pens)	Secukinumab	60	suppressed
Kevzara	Sarilumab	60	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	58	suppressed
Tizanidine Hcl	Tizanidine Hcl	55	18
Acetaminophen-Codeine	Acetaminophen With Codeine	53	11
Pilocarpine Hcl	Pilocarpine Hcl	53	23
Febuxostat	Febuxostat	50	11
Acyclovir	Acyclovir	48	11
Cosentyx Sensoready Pen	Secukinumab	45	suppressed
Taltz Autoinjector	Ixekizumab	45	suppressed
Baclofen	Baclofen	42	16
Dexamethasone	Dexamethasone	42	14
Taltz Syringe	Ixekizumab	39	suppressed
Xeljanz Xr	Tofacitinib Citrate	38	suppressed
Cimzia (2 Pack)	Certolizumab Pegol	36	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	35	suppressed
Mycophenolic Acid	Mycophenolate Sodium	33	suppressed
Omeprazole	Omeprazole	32	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	31	suppressed
Tramadol Hcl Er	Tramadol Hcl	30	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	28	suppressed
Tymlos	Abaloparatide	28	suppressed
Diazepam	Diazepam	25	suppressed
Enbrel Mini	Etanercept	23	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	23	suppressed
Probenecid-Colchicine	Probenecid/Colchicine	23	suppressed
Ibandronate Sodium	Ibandronate Sodium	20	suppressed
Insulin Syringe	Syringe And Needle,insulin,1ml	19	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	19	suppressed
Teriparatide	Teriparatide	19	suppressed
Actemra	Tocilizumab	18	suppressed
Naproxen	Naproxen	18	suppressed
Stelara	Ustekinumab	18	suppressed
Ibuprofen	Ibuprofen	17	suppressed
Savella	Milnacipran Hcl	17	suppressed
Tremfya	Guselkumab	17	suppressed
Carisoprodol	Carisoprodol	16	suppressed
Ondansetron Odt	Ondansetron	16	suppressed
Buprenorphine	Buprenorphine	15	suppressed
Humira(Cf)	Adalimumab	15	suppressed
Promethazine Hcl	Promethazine Hcl	15	suppressed
Cosentyx (2 Syringes)	Secukinumab	14	suppressed
Olumiant	Baricitinib	14	suppressed
Pentazocine-Naloxone Hcl	Pentazocine Hcl/Naloxone Hcl	14	suppressed
Eszopiclone	Eszopiclone	13	suppressed
Mitigare	Colchicine	13	suppressed
Risedronate Sodium Dr	Risedronate Sodium	13	suppressed
Skyrizi Pen	Risankizumab-Rzaa	13	suppressed
Forteo	Teriparatide	12	suppressed
Lidocaine	Lidocaine	12	suppressed
Movantik	Naloxegol Oxalate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error